Cardiovascular effects of ADHD medications in children

Author/s
Gary Stiefel, Professor Frank M. C. Besag
Citation
Issue 2 Spring 2012
CEPiP.2012.1.58-63
Abstract

While methylphenidate, amphetamines and atomoxetine play a significant role in the pharmacological management of ADHD, there have been some safety concerns raised over the last few years with respect to cardiovascular morbidity. The literature has been reviewed, exploring the effects of ADHD medications with respect to sudden death and alterations of heart rate (HR), blood pressure and QT interval. There is some evidence of increased HR and BP using these medications but there is no evidence of a clinically-significant impact. However, most of the published data is on average results and might mask individual cases in which there is a clinically significant change. Regular monitoring of BP and pulse, using the same procedure on each occasion, is recommended. There is no convincing evidence of an association with QT interval prolongation or sudden death. Routine ECGs before starting these medications are not considered to be necessary. However, for each child a careful personal and family history of cardiovascular problems should be taken and a cardiovascular examination should be performed before medication is commenced.

Cite as: Cutting Edge Psychiatry in Practice 2012, 2(1):58-63; https://doi.org/10.65031/zlqn4701

References

  1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry. 2007 Jun;164(6):942-8. https://doi.org/10.1176/ajp.2007.164.6.942
  2. Ford T, Goodman R, Meltzer H. The British child and adolescent mental health survey 1999: The prevalence of DSM-IV disorders. J Am Acad Child Adolesc Psychiatry. 2003 Oct;42(10):1203-11. https://doi.org/10.1097/00004583-200310000-00011
  3. Wilens TE, Prince JB, Spencer TJ, Biederman J. Stimulants and sudden death: What is a physician to do?[see comment]. Pediatrics. 2006 Sep;118(3):1215-9. https://doi.org/10.1542/peds.2006-0942
  4. Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, et al. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry. 2011 Jan;20(1):17-37. https://doi.org/10.1007/s00787-010-0140-6
  5. Rappley MD, Moore JW, Dokken D. ADHD drugs and cardiovascular risk. N Engl J Med. 2006 author reply 2296-8; May 25;354(21):2296-8.           
  6. Knight M. Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death. Pediatrics. 2007 Jan;119(1):154-5. https://doi.org/10.1542/peds.2006-2467
  7. Medicines and healthcare products regulatory agency. drug analysis print: Methylphenidate. [online] available from http://www.mhra.gov.uk/Safetyinformation/Howwemonitorthesafetyofproducts/Medicines/TheYellowCardScheme/YellowCarddata/Druganalysisprints/CON024109?indexChar=M [accessed 2011 Jan 28].            
  8. Aagaard L, Weber CB, Hansen EH. Adverse drug reactions in the paediatric population in Denmark: A retrospective analysis of reports made to the Danish medicines agency from 1998 to 2007. Drug Saf. 2010 Apr 1;33(4):327-39. https://doi.org/10.2165/11319100-000000000-00000
  9. Gould MS, Walsh BT, Munfakh JL, Kleinman M, Duan N, Olfson M, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry. 2009 Sep;166(9):992-1001. https://doi.org/10.1176/appi.ajp.2009.09040472
  10. Kratochvil CJ, Heiligenstein JH, Dittmann R, Spencer TJ, Biederman J, Wernicke J, et al. Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002 Jul;41(7):776-84. https://doi.org/10.1097/00004583-200207000-00008
  11. Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2006 Jan;160(1):82-90. https://doi.org/10.1001/archpedi.160.1.82
  12. McGough JJ, McBurnett K, Bukstein O, Wilens TE, Greenhill L, Lerner M, et al. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2006 Jun;16(3):351-6. https://doi.org/10.1089/cap.2006.16.351
  13. Greenhill LL, Findling RL, Swanson JM, ADHD Study G. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002 Mar;109(3):E39. https://doi.org/10.1542/peds.109.3.e39
  14. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, et al. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics. 2001 Oct;108(4):883-92. https://doi.org/10.1542/peds.108.4.883
  15. Findling RL, Short EJ, McNamara NK, Demeter CA, Stansbrey RJ, Gracious BL, et al. Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007 Nov;46(11):1445-53. https://doi.org/10.1097/chi.0b013e31814b8d3b
  16. Gau SS, Shen HY, Soong WT, Gau CS. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Child Adolesc Psychopharmacol. 2006 Aug;16(4):441-55. https://doi.org/10.1089/cap.2006.16.441
  17. Findling RL, Quinn D, Hatch SJ, Cameron SJ, DeCory HH, McDowell M. Comparison of the clinical efficacy of twice-daily Ritalin and once-daily Equasym XL with placebo in children with attention Deficit/Hyperactivity disorder. Eur Child Adolesc Psychiatry. 2006 Dec;15(8):450-9. https://doi.org/10.1007/s00787-006-0565-0
  18. Wilens TE, Biederman J, Lerner M, Concerta Study G. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: Results from a one-year follow-up study. J Clin Psychopharmacol. 2004 Feb;24(1):36-41. https://doi.org/10.1097/01.jcp.0000106223.36344.df
  19. Wilens T, McBurnett K, Stein M, Lerner M, Spencer T, Wolraich M. ADHD treatment with once-daily OROS methylphenidate: Final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2005 Oct;44(10):1015-23. https://doi.org/10.1097/01.chi.0000173291.28688.e7
  20. Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: A 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006 Feb;28(2):266-79. https://doi.org/10.1016/j.clinthera.2006.02.011
  21. Biederman J, Lopez FA, Boellner SW, Chandler MC. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002 Aug;110(2 Pt 1):258-66. https://doi.org/10.1542/peds.110.2.258
  22. Findling RL, Biederman J, Wilens TE, Spencer TJ, McGough JJ, Lopez FA, et al. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr. 2005 Sep;147(3):348-54. https://doi.org/10.1016/j.jpeds.2005.03.014
  23. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP- 104) in children with attention-deficit/hyperactivity disorder: A phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007 Mar;29(3):450-63. https://doi.org/10.1016/s0149-2918(07)80083-x
  24. Wilens TE, Spencer TJ, Biederman J. Short- and long-term cardiovascular effects of mixed amphetamine salts extended- release in adolescents with ADHD. CNS Spectr. 2005 Oct;10(10 Suppl 15):22-30. https://doi.org/10.1017/s1092852900014115
  25. Donner R, Michaels MA, Ambrosini PJ. Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007 Mar 1;61(5):706-12. https://doi.org/10.1016/j.biopsych.2006.05.002
  26. Findling RL, Childress AC, Krishnan S, McGough JJ. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr. 2008 Jul;13(7):614-20. https://doi.org/10.1017/s1092852900016898
  27. Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf. 2003;26(10):729-40. https://doi.org/10.2165/00002018-200326100-00006
  28. Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002 Dec;63(12):1140-7. https://doi.org/10.4088/jcp.v63n1209
  29. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics. 2001 Nov;108(5):E83. https://doi.org/10.1542/peds.108.5.e83
  30. Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2007 Feb;46(2):242-51. https://doi.org/10.1097/01.chi.0000246056.83791.b6
  31. Donnelly C, Bangs M, Trzepacz P, Zhang S, Witte M, Ball S, et al. Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2009;48(2):176-85. https://doi.org/10.1097/chi.0b013e318193060e
  32. Wilens TE, Newcorn JH, Kratochvil CJ, Gao H, Thomason CK, Rogers AK, et al. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Pediatr. 2006 Jul;149(1):112-9. https://doi.org/10.1016/j.jpeds.2006.01.052
  33. Perrin JM, Friedman RA, Knilans TK, Black Box Working G, Section on Cardiology and Cardiac Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics. 2008 Aug;122(2):451-3. https://doi.org/10.1542/peds.2008-1573
  34. National institute for health and clinical excellence. CG72 Attention deficit hyperactivity disorder. NICE guideline [online]. available from URL: http://guidance.nice.org.uk/CG72/Guidance/pdf/English [accessed 2011 jul 16].           
  35. Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Baker KD, Feldman PD, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006 Aug;45(8):919-27. https://doi.org/10.1097/01.chi.0000222788.34229.68
  36. Spencer T, Biederman J, Heiligenstein J, Wilens T, Faries D, Prince J, et al. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2001;11(3):251-65. https://doi.org/10.1089/10445460152595577
  37. Allen AJ, Kurlan RM, Gilbert DL, Coffey BJ, Linder SL, Lewis DW, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology. 2005 Dec 27;65(12):1941-9. https://doi.org/10.1212/01.wnl.0000188869.58300.a7
  38. Cooper WO, Habel LA, Sox CM et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011 Nov 17;365(20):1896-904.
  39. Stiefel G, Besag F. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf. 2010 Oct 1;33(10):821-42. https://doi.org/10.2165/11536380-000000000-00000
  40. Findling RL, Biederman J, Wilens TE, et al. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr 2005 Sep; 147 (3): 348-54 https://doi.org/10.1016/j.jpeds.2005.03.014
  41. Wilens TE, Spencer TJ, Biederman J. Short- and long-term cardiovascular effects of mixed amphetamine salts extended- release in adolescents with ADHD. CNS Spectr 2005 Oct; 10 (10 Suppl. 15): 22-30 https://doi.org/10.1017/s1092852900014115
  42. Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 2007 Mar; 29 (3): 450-63 https://doi.org/10.1016/s0149-2918(07)80083-x
  43. Donner R, Michaels MA, Ambrosini PJ. Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorder. Biol Psychiatry 2007 Mar 1; 61 (5): 706-12 https://doi.org/10.1016/j.biopsych.2006.05.002
  44. Findling RL, Childress AC, Krishnan S, et al. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr 2008 Jul; 13 (7): 614-20 https://doi.org/10.1017/s1092852900016898
  45. Prasad S, Furr AJ, Zhang S et al. Baeline values from the electrocardiograms of children and adolescents with ADHD. Child Adolesc Psychiatry Ment Health. 2007 Sep; 1(1):11 https://doi.org/10.1186/1753-2000-1-11
  46. Medicines and Healthcare Products Regulatory Agency. Strattera (atomoxetine) – preliminary assessment report December 2005 [online]. Available from URL: http://www.mhra.gov.uk/home/groups/es-foi/documents/foidisclosure/con2024013.pdf [Accessed 2011 Jan 16]